With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 5,634.58 and the Dow Jones Industrial Average DJIA falling 0.

An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due to expensive valuation. See more.

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped revenue to soar in the double digits -- and that's resulted in a surging share price too,

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 589.81% and currently trading at $912.00. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,